There are drug trial failures. And there are drug trial failures. The recent move by drug giant Biogen to halt their Alzheimer’s drug has not only been a setback for the company—their stock fell precipitously on the news—it’s also been a major setback for the whole research community focused on this disease. The Biogen trial was one of the last of the major drug companies with high hopes for a significant therapeutic step forward for the neurodegenerative disease. The last five years has seen one big pharma players after another throw in the towel.
Share this post

Reassessing Alzheimer’s with Larry Goldstein, UCSD
www.mendelspod.com
Reassessing Alzheimer’s with Larry Goldstein, UCSD
Apr 9, 2019
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Listen on
Substack App
Apple Podcasts
RSS Feed
Reassessing Alzheimer’s with Larry Goldstein, UCSD